GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » Price-to-Owner-Earnings

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Price-to-Owner-Earnings : (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals Price-to-Owner-Earnings?

As of today (2024-04-26), Keryx Biopharmaceuticals's share price is $3.36. Keryx Biopharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Keryx Biopharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


KERX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.115
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-26), Keryx Biopharmaceuticals's share price is $3.36. Keryx Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.75. Therefore, Keryx Biopharmaceuticals's PE Ratio (TTM) for today is At Loss.

As of today (2024-04-26), Keryx Biopharmaceuticals's share price is $3.36. Keryx Biopharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.75. Therefore, Keryx Biopharmaceuticals's PE Ratio without NRI for today is At Loss.

During the past 13 years, Keryx Biopharmaceuticals's highest PE Ratio without NRI was 50.19. The lowest was 0.00. And the median was 12.32.


Keryx Biopharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Keryx Biopharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals Price-to-Owner-Earnings Chart

Keryx Biopharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Keryx Biopharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Keryx Biopharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, Keryx Biopharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keryx Biopharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's Price-to-Owner-Earnings falls into.



Keryx Biopharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Keryx Biopharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.36/-1.10
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keryx Biopharmaceuticals  (NAS:KERX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Keryx Biopharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.
Executives
Scott A Holmes officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison director, officer: Interim CEO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma director, 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison director, officer: President and CEO ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams officer: General Counsel and Secretary 750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022